Efficacy and quality of life changes in switching traditional rapid acting insulin to ultra rapid Lispro in patients with type 2 diabetes

Efficacy and quality of life changes in switching traditional rapid acting insulin to ultra rapid Lispro in patients with type 2 diabetes - Efficacy and quality of life changes in switching traditional rapid acting insulin to ultra rapid Lispro in patients with type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000048528

Enrollment

Registered

2022-08-04

Start date

2022-08-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

Have patients fill out the insulin selection sheet. Patients who are judged to be more suitable for ultra rapid Lispro and who wish to change to it are required to answer the questionnaire (Insulin Th

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Type 2 diabetes patients who have been treated with traditional rapid acting fast-acting insulin for more than 6 months before the study 2) Patients who are judged to be more suitable for ultra rapid Lispro from the insulin selection sheet

Exclusion criteria

Exclusion criteria: 1) Patients allergic to insulin lispro 2) Patients who cannot administer ultra rapid Lispro within 2 minutes before meals and within 20 minutes from the start of meals when necessary.

Design outcomes

Primary

Measure	Time frame
Changes in Time in range from Freestyle Libre Pro data and ITR-QOL score by switching traditional rapid acting insulin to ultra rapid Lispro.	—

Countries

Japan

Contacts

Public ContactYuriko Hajika

Minami Osaka Hospital Internal Medicine

y.hajika@minamiosaka.com06-6685-0221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026